PARK7 and neoplasm: PARK7 is upregulated in 83.3% of patients with cholangiocarcinoma [39] and in 85% of patients with laryngeal squamous cell cancer [40], which is significantly correlated with the poor survival and tumor recurrence of patients with laryngeal squamous cell cancer [40,57,58].